Q2, FY 2021 Results: Mytheresa Continues Strong Growth and Profitability
25.2.2021 14:12:00 EET | Business Wire | Press release
MYT Netherlands Parent B.V. (NYSE:MYTE) (“Mytheresa” or the “Company”), the parent company of Mytheresa Group GmbH, today announced financial results for its fiscal second quarter ended December 31, 2020.
Michael Kliger, Chief Executive Officer of Mytheresa, said, “Even considering clear tailwinds by the COVID pandemic, the strong results of the second quarter of fiscal year 2021 confirm once more our strategy and unique business model: Mytheresa is about inspiration not aggregation. It is about an unrivaled, highly curated offering, a focus on high-end luxury customers, sophisticated technologies and a first-class in-house managed service experience.”
Kliger continued, “Our full commitment to acquire and retain the best customer base in the market creates a reinforcing cycle of outstanding brand relationships that feed a superior customer value proposition to generate strong customer economics, which allows us to stay true to our strategic focus. Therefore, we will continue to deliver growth as well as profitability.”
FINANCIAL HIGHLIGHTS FOR THE SECOND QUARTER ENDED DECEMBER 31, 2020
- Net sales increase of 32.9% year-over-year to €158.6 million
- Active customer growth of 28.2% to 569,000
- Gross margin of 49.5%, a slight increase of 60 basis points year-over-year
- Adjusted EBITDA of €22.1 million, as compared to €12.9 million in the prior year period
- Adjusted EBITDA margin of 14.0%, as compared to 10.8% in the prior year period
- Operating income of €16.6 million, as compared to €7.3 million in the prior year period
- Adjusted operating income of €20.1 million, as compared to €10.9 million in the prior year period
- Net income of €15.7 million, as compared to €6.3 million in the prior year period
- Adjusted net income of €14.8 million, as compared to €6.4 million in the prior year period
- Successfully completed IPO in January 2021 to raise proceeds, net of underwriting discounts and before related expenses of approximately $344.2 million
FINANCIAL HIGHLIGHTS FOR THE SIX MONTHS ENDED DECEMBER 31, 2020
- Net sales increase of 30.4% year-over-year to €285.0 million
- Gross margin of 48.2%, a slight increase of 20 basis points year-over-year
- Adjusted EBITDA of €32.6 million, as compared to €17.2 million in the prior year period
- Adjusted EBITDA margin of 11.4%, as compared to 7.9% in the prior year period
- Operating income of €24.8 million, as compared to €8.9 million in the prior year period
- Adjusted Operating income of €28.5 million, as compared to €13.4 million in the prior year period.
- Net income of €25.4 million, as compared to €2.0 million in the prior year period
- Adjusted net income of €20.1 million, as compared to €10.0 million in the prior year period
RECENT BUSINESS HIGHLIGHTS
- Maintained business continuity in all operations with focus on health and well-being of all Mytheresa employees as top priority since the pandemic started
- Record number of daily shipments, processing 11,000 parcels in just one day during Q2, FY 2021
- Record high of first time buyers (over 100,000 new customers) in Q2, FY 2021
- Further decreased customer acquisition costs
- Significant increase in customer satisfaction with a Net Promoter Score of 87% in Q2, FY 2021
- Continued expansion of the Mytheresa menswear business above expectations with net sales share surpassing 10% in December 2020
- Hosted digital events targeting top customers in collaboration with the designers of Khaite, Wardrobe NYC, Eera, selected influencers and a physical VIC event in Shanghai, China in December 2020
- Strong ongoing support of brand partners with the launch of exclusive capsule collections and pre-launches in collaboration with Valentino, Moncler, Dolce & Gabbana, Loewe, Christian Louboutin, Max Mara and many more
SUBSEQUENT EVENTS
On January 25, 2021, Mytheresa successfully closed its initial public offering (“IPO”) of 17,994,117 American Depositary Shares (“ADSs”), representing 17,994,117 ordinary shares, including the full exercise by the underwriters of their option to purchase 2,347,058 additional ADSs, representing 2,347,058 ordinary shares, at a public offering price of $26.00 per ADS. The Company sold 14,233,823 ADSs in the offering and its sole shareholder sold 3,760,294 ADSs in the offering, including 586,764 ADSs sold by the Company and 1,760,294 ADSs sold by the sole shareholder pursuant to the exercise in full of the underwriters’ option to purchase additional ADSs. The IPO raised approximately $344.2 million, net of underwriting discounts and before related expenses.
On January 26, 2021, Mytheresa exercised the option to repay the Fixed Rate Shareholder Loans (principal plus outstanding interest) with parts of the proceeds of our IPO, which resulted in cash outflows of €170.0 million ($ 206.6 million). In addition, MGG and its subsidiaries fully repaid any borrowings under the revolving credit facilities.
BUSINESS OUTLOOK
For the full fiscal year ending June 30, 2021, some of the beneficial performance tailwinds from COVID may be expected to slow down in Q3 and especially in Q4 as stores reopen. Nevertheless, we expect strong results for the full fiscal year in line with long-term expectations of net sales growth of low to mid-twenties and stable Adjusted EBITDA margins:
- Net sales in the range of €565 million to €580 million, representing 26% to 29% growth
- Adjusted EBITDA in the range of €45 million to €48 million, representing 27% to 36% growth
- Adjusted EBITDA Margin of 8.0% to 8.3%
The foregoing forward-looking statements reflect Mytheresa’s expectations as of today's date. Given the number of risk factors, uncertainties and assumptions discussed below, actual results may differ materially. Mytheresa does not intend to update its forward-looking statements until its next quarterly results announcement, other than in publicly available statements.
CONFERENCE CALL AND WEBCAST INFORMATION
Mytheresa will host a conference call to discuss its second quarter fiscal 2021 financial results on February 25, 2021 at 8:00am Eastern Time. Those wishing to participate via webcast should access the call through Mytheresa’s Investor Relations website at https://investors.mytheresa.com. Those wishing to participate via the telephone may dial in at +1 (833) 979-2860 (USA) or +1 (236) 714-2917 (International). A replay will be available via webcast through Mytheresa’s Investor Relations website. The telephone replay will be available from 11:00am Eastern Time on February 25, 2021, through March 4, 2021, by dialing +1 (800) 585-8367 (USA) or +1 (416) 621-4642 (International). The replay passcode will be 9993744.
FORWARD LOOKING STATEMENTS
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements relating to the impact of the COVID-19 global pandemic; future sales, expenses, and profitability; future development and expected growth of our business and industry; our ability to execute our business model and our business strategy; having available sufficient cash and borrowing capacity to meet working capital, debt service and capital expenditure requirements for the next twelve months; and projected capital spending. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements are only predictions Actual events or results may differ materially from those stated or implied by these forward-looking statements. In evaluating these statements and our prospects, you should carefully consider the factors set forth below.
We undertake no obligation to update any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
The achievement or success of the matters covered by such forward-looking statements involves known and unknown risks, uncertainties and assumptions. If any such risks or uncertainties materialize or if any of the assumptions prove incorrect, our results could differ materially from the results expressed or implied by the forward-looking statements we make.
You should not rely upon forward-looking statements as predictions of future events. Forward-looking statements represent our management’s beliefs and assumptions only as of the date such statements are made.
Further information on these and other factors that could affect our financial results is included in filings we make with the U.S. Securities and Exchange Commission (“SEC”) from time to time, including the section titled “Risk Factors” in our final prospectus under Rule 424(b) filed with the SEC on January 22, 2021 in connection with our IPO and 6-K (reporting our quarterly results). These documents are available on the SEC’s website at www.sec.gov and on the SEC Filings section of the Investor Relations section of our website at: https://investors.mytheresa.com.
ABOUT NON-IFRS FINANCIAL MEASURES
We review a number of operating and financial metrics, including the following business and non-IFRS metrics, to evaluate our business, measure our performance, identify trends affecting our business, formulate business plans and make strategic decisions. We present Adjusted EBITDA, Adjusted Operating Income, and Adjusted Net Income because they are frequently used by analysts, investors and other interested parties to evaluate companies in our industry. Further, we believe these measures are helpful in highlighting trends in our operating results, because they exclude the impact of items that are outside the control of management or not reflective of our ongoing operations and performance. Adjusted EBITDA, Adjusted Operating Income, and Adjusted Net Income have limitations, because they exclude certain types of expenses. Furthermore, other companies in our industry may calculate similarly titled measures differently than we do, limiting their usefulness as comparative measures. We use Adjusted EBITDA, Adjusted Operating Income, and Adjusted Net Income as supplemental information only. You are encouraged to evaluate each adjustment and the reasons we consider it appropriate for supplemental analysis.
Our non-IFRS financial measures include:
- Adjusted EBITDA is a non-IFRS financial measure that we calculate as net income before finance expense (net), taxes, and depreciation and amortization, adjusted to exclude U.S. sales tax expenditures temporarily borne by us through the fourth quarter of fiscal 2020, IPO preparation and transaction costs and share-based compensation expenses.
- Adjusted Operating Income is a non-IFRS financial measure that we calculate as operating income, adjusted to exclude U.S. sales tax expenditures temporarily borne by us through the fourth quarter of fiscal 2020, any IPO preparation and transaction costs and share-based compensation expenses.
- Adjusted Net Income is a non-IFRS financial measure that we calculate as net income, adjusted to exclude U.S. sales tax expenditures temporarily borne by us, finance expenses on our Shareholder Loans, IPO preparation and transaction costs, share-based compensation expenses and related income tax effects.
ABOUT MYTHERESA
Mytheresa is one of the leading global luxury fashion e-commerce retailers. Mytheresa was launched in 2006 and offers ready-to-wear, shoes, bags and accessories for women, men and kids. The highly curated edit focuses on true luxury with designer brands such as Bottega Veneta, Burberry, Dolce & Gabbana, Fendi, Gucci, LOEWE, Loro Piana, Moncler, Prada, Saint Laurent, Valentino and many more. Mytheresa's unique digital experience is based on a sharp focus on high-end luxury shoppers, exclusive product and content offerings, leading technology and analytical platforms as well as high quality service operations.
For more information, please visit https://investors.mytheresa.com/.
MYT Netherlands Parent B.V.
Financial Results and Key Operating Metrics
(Amounts in € millions)
|
|
Three Months Ended |
|
Six Months Ended |
|||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
December
|
|
December
|
|
Change
|
|
December
|
|
December
|
|
Change
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
(in millions) (unaudited) |
|
|
|
|
|
|
|
|
|
|||||
|
Active customer (LTM in thousands) |
444 |
|
569 |
|
28.2% |
|
444 |
|
569 |
|
28.2% |
|||
|
Total orders shipped (LTM in thousands) |
1.010 |
|
1.256 |
|
24.4% |
|
1.010 |
|
1.256 |
|
24.4% |
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
Net sales |
€ 119.4 |
|
€ 158.6 |
|
32.9% |
|
€ 218.5 |
|
€ 285.0 |
|
30.4% |
|||
|
Gross profit |
€ 58.4 |
|
€ 78.6 |
|
34.6% |
|
€ 104.7 |
|
€ 137.3 |
|
31.1% |
|||
|
Gross profit margin(1) |
48.9% |
|
49.5% |
|
63 BPs |
|
47.9% |
|
48.2% |
|
23 BPs |
|||
|
Adjusted EBITDA(2) |
€ 12.9 |
|
€ 22.1 |
|
72.1% |
|
€ 17.2 |
|
€ 32.6 |
|
89.1% |
|||
|
Adjusted EBITDA margin(1) |
10.8% |
|
14.0% |
|
318 BPs |
|
7.9% |
|
11.4% |
|
355 BPs |
|||
|
Adjusted Operating Income(2) |
€ 10.9 |
|
€ 20.1 |
|
84.7% |
|
€ 13.4 |
|
€ 28.5 |
|
113.3% |
|||
|
Adjusted Operating Income margin(1) |
9.1% |
|
12.7% |
|
356 BPs |
|
6.1% |
|
10.0% |
|
389 BPs |
|||
|
Adjusted Net Income(2) |
€ 6.4 |
|
€ 14.8 |
|
131.4% |
|
€ 10.0 |
|
€ 20.1 |
|
101.5% |
|||
|
Adjusted Net Income margin(1) |
5.4% |
|
9.3% |
|
397 BPs |
|
4.6% |
|
7.0% |
|
248 BPs |
|||
|
(1) |
As a percentage of net sales. |
|
|
(2) |
EBITDA, adjusted EBITDA, adjusted Operating Income, adjusted net income are measures not defined under IFRS. For further information about how we calculate these measures and limitations of its use, see below. |
MYT Netherlands Parent B.V.
Financial Results and Key Operating Metrics
(Amounts in € millions)
The following are reconciliations of Adjusted EBITDA, Adjusted Operating Income, and Adjusted Net Income to their most directly comparable IFRS measures:
|
|
Three Months Ended |
Six Months Ended |
||||||||||
|
|
|
|
|
|
|
|
||||||
|
|
December
|
December
|
Change
|
December
|
December
|
Change
|
||||||
|
|
|
|
|
|
|
|
||||||
|
(in millions) (unaudited) |
|
|
|
|
|
|
||||||
|
Net income |
€ 6.3 |
€ 15.7 |
148.4% |
€ 2.0 |
€ 25.4 |
1,159.4% |
||||||
|
Finance expenses, net |
€ (3.4) |
€ (5.0) |
46.8% |
€ 6.0 |
€ (10.2) |
(269.7%) |
||||||
|
Income tax expense |
€ 4.4 |
€ 5.9 |
33.3% |
€ 0.9 |
€ 9.6 |
1026.0% |
||||||
|
Depreciation and amortization |
€ 2.0 |
€ 2.0 |
3.0% |
€ 3.9 |
€ 4.1 |
5.3% |
||||||
|
thereof depreciation of right-of use assets |
€ 1.3 |
€ 1.3 |
2.3% |
€ 2.5 |
€ 2.6 |
4.4% |
||||||
|
EBITDA |
€ 9.3 |
€ 18.7 |
100.1% |
€ 12.7 |
€ 28.9 |
127.1% |
||||||
|
U.S. sales tax(1) |
€ 0.8 |
€ 0.0 |
(100.0%) |
€ 1.7 |
€ 0.0 |
(100.0%) |
||||||
|
IPO preparation and transaction costs(2) |
€ 2.7 |
€ 3.5 |
27.9% |
€ 2.7 |
€ 3.7 |
35.3% |
||||||
|
Share-based compensation expense(3) |
€ 0.0 |
€ 0.0 |
(68.2%) |
€ 0.1 |
€ 0.0 |
(72.5%) |
||||||
|
Adjusted EBITDA |
€ 12.9 |
€ 22.1 |
72.1% |
€ 17.2 |
€ 32.6 |
89.1% |
||||||
|
|
Three Months Ended |
|
Six Months Ended |
|||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December
|
|
December
|
|
Change
|
|
December
|
|
December
|
|
Change
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(in millions) (unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating Income |
€ 7.3 |
|
€ 16.6 |
|
126.4% |
|
€ 8.9 |
|
€ 24.8 |
|
180.3% |
|
|
U.S. sales tax(1) |
€ 0.8 |
|
€ 0.0 |
|
(100.0%) |
|
€ 1.7 |
|
€ 0.0 |
|
(100.0%) |
|
|
IPO preparation and transaction costs(2) |
€ 2.7 |
|
€ 3.5 |
|
27.9% |
|
€ 2.7 |
|
€ 3.7 |
|
35.3% |
|
|
Share-based compensation expense(3) |
€ 0.0 |
|
€ 0.0 |
|
(68.2%) |
|
€ 0.1 |
|
€ 0.0 |
|
(72.5%) |
|
|
Adjusted Operating Income |
€ 10.9 |
|
€ 20.1 |
|
84.7% |
|
€ 13.4 |
|
€ 28.5 |
|
113.3% |
|
MYT Netherlands Parent B.V.
Financial Results and Key Operating Metrics
(Amounts in € millions)
|
|
Three Months Ended |
|
Six Months Ended |
|||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December
|
|
December
|
|
Change
|
|
December
|
|
December
|
|
Change
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(in millions) (unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Income |
€ 6.3 |
|
€ 15.7 |
|
148.4% |
|
€ 2.0 |
|
€ 25.4 |
|
1,156.4% |
|
|
U.S. sales tax(1) |
€ 0.8 |
|
€ 0.0 |
|
(100.0%) |
|
€ 1.7 |
|
€ 0.0 |
|
(100.0%) |
|
|
IPO preparation and transaction costs(2) |
€ 2.7 |
|
€ 3.5 |
|
27.9% |
|
€ 2.7 |
|
€ 3.7 |
|
35.3% |
|
|
Share-based compensation expense(3) |
€ 0.0 |
|
€ 0.0 |
|
(68.2%) |
|
€ 0.1 |
|
€ 0.0 |
|
(72.5%) |
|
|
Finance expenses on shareholder loans (4) |
€ (3.7) |
|
€ (5.3) |
|
44.3% |
|
€ 5.6 |
|
€ (10.9) |
|
(296.1%) |
|
|
Income tax effect(5) |
€ 0.2 |
|
€ 0.9 |
|
338.9% |
|
€ (2.1) |
|
€ 1.9 |
|
(190.5%) |
|
|
Adjusted Net Income |
€ 6.4 |
|
€ 14.8 |
|
131.4% |
|
€ 10.0 |
|
€ 20.1 |
|
101.5% |
|
|
(1) |
Represents expenses related to sales tax liabilities temporarily borne by us through the fourth quarter of fiscal 2020 in the United States. We temporarily incurred sales tax related liabilities on customer purchases in the United States because we were not able to charge our customers for these amounts at the point of sale under our previous IT configuration. Due to upgrades in our IT infrastructure during the fourth quarter of fiscal 2020, we no longer incur these expenses, as we charge the applicable U.S. sales tax directly to our customers. |
|
|
(2) |
Represents non-recurring professional fees, including consulting, legal and accounting fees, related to this offering, which are classified within selling, general and administrative expenses. |
|
|
(3) |
During the three and six months ended December 31, 2019 and 2020, respectively, certain key management personnel received share-based compensation from our ultimate parent. We do not consider these expenses to be indicative of our core operating performance. |
|
|
(4) |
Our Adjusted Net Income excludes finance expenses associated with our Shareholder Loans, which we do not consider to be indicative of our core performance. We did not receive any cash proceeds under the Shareholder Loans, which originated as part of the Neiman Marcus acquisition in 2014. Further, we do not have any financial covenants associated from the Shareholder Loans and we do not have any required interest or principal payments until their respective maturities in October 2025. In January 2021, we repaid our Shareholder Loans (principal plus outstanding interest) using a portion of the net proceeds from our initial public offering. |
|
|
(5) |
Reflects adjustments to historical income tax expense to reflect changes in taxable income for each of the periods presented due to changes in finance expenses related to the Shareholder Loans, assuming a statutory tax rate of 27.8%. |
MYT Netherlands Parent B.V.
Unaudited Condensed Consolidated Statements of Profit and Comprehensive Income
(Amounts in € thousands, except share and per share data)
|
|
|
Three Months Ended |
|
Six Months Ended |
||||||||
|
|
|
|
|
|
|
|
||||||
|
(in € thousands) |
|
December
|
December
|
|
December
|
|
December
|
|||||
|
|
|
|
|
|
|
|
|
|||||
|
Net sales |
|
119,369 |
158,593 |
|
218,481 |
|
284,952 |
|||||
|
Cost of sales, exclusive of depreciation and amortization |
|
(60,989) |
(80,023) |
|
(113,755) |
|
(147,701) |
|||||
|
Gross profit |
|
58,380 |
78,570 |
|
104,726 |
|
137,251 |
|||||
|
Shipping and payment cost |
|
(14,204) |
(17,833) |
|
(27,345) |
|
(32,666) |
|||||
|
Marketing expenses |
|
(17,294) |
(19,696) |
|
(33,110) |
|
(37,137) |
|||||
|
Selling, general and administrative expenses |
|
(17,839) |
(22,104) |
|
(31,794) |
|
(37,660) |
|||||
|
Depreciation and amortization |
|
(1,987) |
(2,046) |
|
(3,864) |
|
(4,067) |
|||||
|
Other expense (income), net |
|
284 |
(276) |
|
244 |
|
(897) |
|||||
|
Operating income |
|
7,340 |
16,615 |
|
8,857 |
|
24,824 |
|||||
|
Finance (expense) income, net |
|
3,389 |
4,975 |
|
(5,984) |
|
10,157 |
|||||
|
Income (loss) before income taxes |
|
10,729 |
21,590 |
|
2,873 |
|
34,981 |
|||||
|
Income tax expense (income) |
|
(4,399) |
(5,866) |
|
(855) |
|
(9,627) |
|||||
|
Net income (loss) |
|
6,330 |
15,724 |
|
2,018 |
|
25,354 |
|||||
|
Cash Flow Hedge |
|
436 |
78 |
|
(846) |
|
949 |
|||||
|
Income Taxes related to Cash Flow Hedge |
|
(121) |
11 |
|
235 |
|
(231) |
|||||
|
Other comprehensive income (loss) |
|
315 |
89 |
|
(611) |
|
718 |
|||||
|
Comprehensive income (loss) |
|
6,645 |
15,813 |
|
1,407 |
|
26,072 |
|||||
|
|
|
|
|
|
|
|
|
|||||
|
Basic and diluted earnings per share |
€ |
0,09 |
0,22 |
€ |
0,03 |
€ |
0,36 |
|||||
|
Weighted average ordinary shares outstanding (basic and diluted)(1) |
|
70,190,687 |
70,190,687 |
|
70,190,687 |
|
70,190,687 |
|||||
|
(1) |
On January 12, 2021, the Company effected a 70,190,687 (with a nominal value per share of €0.000015) for one share split of its ordinary shares outstanding. Accordingly, all share and per share amounts for all periods presented in these condensed consolidated interim financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect this share split. |
MYT Netherlands Parent B.V.
Unaudited Condensed Consolidated Statements of Financial Position
(Amounts in € thousands)
|
(in € thousands) |
|
June 30, 2020 |
December 31, 2020 |
|||
|
Assets |
|
|||||
|
Non-current assets |
|
|||||
|
Intangible assets and goodwill |
|
154,966 |
154,883 |
|||
|
Property and equipment, net |
|
|
|
9,570 |
|
9,517 |
|
Right-of-use assets |
|
19,001 |
16,298 |
|||
|
Total non-current assets |
|
183,537 |
180,698 |
|||
|
Current assets |
|
|
||||
|
Inventories |
|
|
|
169,131 |
|
231,968 |
|
Trade and other receivables |
|
4,815 |
6,012 |
|||
|
Other assets |
|
|
|
18,950 |
|
18,180 |
|
Cash and cash equivalents |
|
9,367 |
5,231 |
|||
|
Total current assets |
|
|
|
202,263 |
|
261,391 |
|
Total assets |
|
385,800 |
442,089 |
|||
|
|
|
|||||
|
Shareholders’ equity and liabilities |
|
|
||||
|
Subscribed capital |
|
1 |
1 |
|||
|
Capital reserve |
|
|
|
91,008 |
|
91,022 |
|
Accumulated Deficit |
|
(28,234) |
(2,880) |
|||
|
Other comprehensive income |
|
|
|
1,602 |
|
2,320 |
|
Total shareholders’ equity |
|
64,377 |
90,463 |
|||
|
|
|
|||||
|
Non-current liabilities |
|
|
|
|
|
|
|
Shareholder Loans |
|
191,194 |
174,651 |
|||
|
Other liabilities |
|
|
5,905 |
|
7,240 |
|
|
Tax liabilities |
3,853 |
3,852 |
||||
|
Provisions |
|
|
582 |
|
706 |
|
|
Lease liabilities |
13,928 |
11,338 |
||||
|
Deferred tax liabilities, net |
|
|
1,130 |
|
9,882 |
|
|
Total non-current liabilities |
216,592 |
207,669 |
||||
|
Current liabilities |
|
|
|
|
|
|
|
Liabilities to banks |
10,000 |
45,990 |
||||
|
Lease liabilities |
|
|
5,787 |
|
5,239 |
|
|
Contract liabilities |
6,758 |
6,024 |
||||
|
Trade and other payables |
|
|
36,158 |
|
38,708 |
|
|
Other liabilities |
46,128 |
47,996 |
||||
|
Total current liabilities |
|
|
104,831 |
|
143,957 |
|
|
Total liabilities |
321,423 |
351,626 |
||||
|
Total shareholders’ equity and liabilities |
|
|
385,800 |
|
442,089 |
MYT Netherlands Parent B.V.
Unaudited Condensed Consolidated Statements of Changes in Equity
(Amounts in € thousands)
|
(in € thousands) |
|
Subscribed
|
|
Capital
|
|
Accumulated
|
|
Hedging
|
|
Foreign currency
|
|
Total
|
|
Balance as of July 1, 2019 |
|
72 |
|
148,960 |
|
(34,584) |
|
- |
|
(3,128) |
|
111,320 |
|
Net income |
|
- |
|
- |
|
2,018 |
|
- |
|
- |
|
2,018 |
|
Other comprehensive income |
|
- |
|
- |
|
- |
|
(611) |
|
1,224 |
|
613 |
|
Comprehensive income |
|
- |
|
- |
|
2,018 |
|
(611) |
|
1,224 |
|
2,631 |
|
Legal Reorganization |
|
(71) |
|
36,252 |
|
|
|
- |
|
- |
|
36,181 |
|
Share-based compensation |
|
- |
|
51 |
|
- |
|
- |
|
- |
|
51 |
|
Balance as of December 31, 2019 |
|
1 |
|
185,263 |
|
(32,566) |
|
(611) |
|
(1.904) |
|
150,183 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of July 1, 2020 |
|
1 |
|
91,008 |
|
(28,234) |
|
- |
|
1,602 |
|
64,377 |
|
Net income |
|
- |
|
- |
|
25,354 |
|
- |
|
- |
|
25,354 |
|
Other comprehensive income |
|
- |
|
- |
|
- |
|
718 |
|
- |
|
718 |
|
Comprehensive income |
|
- |
|
- |
|
25,354 |
|
718 |
|
- |
|
26,072 |
|
Share-based compensation |
|
- |
|
14 |
|
|
|
- |
|
|
|
14 |
|
Balance as of December 31, 2020 |
|
1 |
|
91,022 |
|
(2,880) |
|
718 |
|
1,602 |
|
90,463 |
MYT Netherlands Parent B.V.
Unaudited Condensed Consolidated Statements of Cash Flows
(Amounts in € thousands)
|
Six months ended December 31, |
||||||
|
(in € thousands) |
2019 |
2020 |
||||
|
Net (loss) income |
|
|
|
2,018 |
|
25,354 |
|
Non-Cash items |
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
|
3,864 |
|
4,067 |
|
Finance expense (income), net |
|
|
|
5,984 |
|
(10,157) |
|
Share-based compensation |
|
|
|
51 |
|
14 |
|
Income tax (income) expense |
|
|
|
855 |
|
9,627 |
|
Change in operating assets and liabilities |
|
|
|
|
|
|
|
Increase in provisions |
|
|
|
8 |
|
124 |
|
Increase in inventories |
|
|
|
(36,418) |
|
(62,837) |
|
Decrease (increase) in trade and other receivables |
|
|
|
1,499 |
|
(1,197) |
|
Decrease (increase) in other assets |
|
|
|
1,072 |
|
1,955 |
|
Increase in other liabilities |
|
|
|
8,726 |
|
2,968 |
|
Increase (decrease) in contract liabilities |
|
|
|
1,528 |
|
(734) |
|
(Decrease) increase in trade and other payables |
|
|
|
(7,949) |
|
2,550 |
|
Income taxes paid |
|
|
|
(1,723) |
|
(1,102) |
|
Net cash (outflow) from operating activities |
|
|
|
(20,485) |
|
(29,368) |
|
Expenditure for property and equipment and intangible assets |
|
|
|
(1,281) |
|
(1,363) |
|
Proceeds from sale of property and equipment and intangible assets |
|
|
|
- |
|
44 |
|
Net cash (outflow) from investing activities |
|
|
|
(1,281) |
|
(1,319) |
|
Interest paid |
|
|
|
(418) |
|
(3,962) |
|
Proceeds from bank liabilities |
|
|
|
30,000 |
|
64,990 |
|
Repayment of liabilities from banks |
|
|
|
(862) |
|
(29,000) |
|
Repayment of Shareholder loans |
|
|
|
- |
|
(2,411) |
|
Lease payments |
|
|
|
(2,465) |
|
(3,047) |
|
Net cash inflow from financing activities |
|
|
|
26,255 |
|
26,570 |
|
Net increase (decrease) in cash and cash equivalents |
|
|
|
4,489 |
|
(4,118) |
|
Cash and cash equivalents at the beginning of the period |
|
|
|
2,120 |
|
9,367 |
|
Effects of exchange rate changes on cash and cash equivalents |
|
|
|
(28) |
|
(18) |
|
Cash and cash equivalents at end of the period |
|
|
|
6,581 |
|
5,231 |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210225005293/en/
Contact information
Investor Relations Contacts
Ed Yuen / Maria Lycouris
+1-800-929-7167
investors@mytheresa.com
Media Contacts for public relations
Mytheresa.com GmbH
Sandra Romano
mobile: +49 152 54725178
phone: +49 89 127695-236
email: sandra.romano@mytheresa.com
Media Contacts for business press
Edelman USA
Ted McHugh / Nicole Briguet
phone: +1 201 341-0211 / +1 646 750-7235
email: ted.mchugh@edelman.com
email: nicole.briguet@edelman.com
Edelman Germany, Austria, Switzerland
Ruediger Assion
mobile: +49 162 4909624
phone: +49 221 8282 8111
email: ruediger.assion@edelmann.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VerSprite Launches Fork and Knife: AI-Driven Threat Modeling and Adversarial Testing Built for the Speed of Modern Software27.6.2026 00:28:00 EEST | Press release
VerSprite, a global leader in risk-based threat modeling and the firm behind the PASTA (Process for Attack Simulation and Threat Analysis) methodology, today announced the general availability of Fork (www.forktm.com), a continuous application threat modeling platform, alongside Knife, an AI-led, human-on-the-loop adversarial testing platform for web applications and web API endpoints. Together, the two products operationalize a new model for product security—one where applications are securely designed, continuously modeled, and actively tested as part of the build process itself. The launch addresses a problem every security leader knows but few tools have solved: threat modeling is essential, never more so than in an AI-driven era, yet it has remained slow, manual, and anchored to frameworks designed for a different threat landscape. The problem: threat modeling matters more than ever—and most tools are stuck in 2005 For two decades, application threat modeling has leaned heavily on
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release
Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
